Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

725 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors associated with disease-specific life impact in patients with hidradenitis suppurativa: results from the Global VOICE project.
Garg A, Rawal S, Akilov O, Alavi A, Ardon C, Bechara FG, Cohen AD, Cohen SR, Daveluy S, Del Marmol V, Delage M, Esmann S, Fisher S, Giamarellos-Bourboulis EJ, Glowaczewska A, Goldfarb N, Brant EG, Grimstad Ø, Guilbault S, Hamzavi I, Hughes R, Ingram JR, Jemec GBE, Ju Q, Kappe N, Kirby B, Kirby JS, Lowes MA, Matusiak L, Micha S, Micheletti RG, Miller AP, Moseng D, Naik HB, Nassif A, Nikolakis G, Paek SY, Pascual JC, Prens E, Resnik B, Riad H, Sayed C, Smith SD, Soliman Y, Szepietowski JC, Tan J, Thorlacius L, Tzellos T, van der Zee HH, Villumsen B, Wang L, Zouboulis CC, Strunk A. Garg A, et al. Among authors: zouboulis cc. Br J Dermatol. 2023 May 24;188(6):808-810. doi: 10.1093/bjd/ljad069. Br J Dermatol. 2023. PMID: 36891871 No abstract available.
Isotretinoin-associated acne fulminans: A multicentre, retrospective study of the European Academy of Dermatology and Venereology Task Force on Acne, Rosacea and Hidradenitis Suppurativa.
Dessinioti C, Dréno B, Bettoli V, Vural S, Brzezinski P, Nassif A, Svensson Å, Zouboulis CC. Dessinioti C, et al. Among authors: zouboulis cc. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):197-204. doi: 10.1111/jdv.19477. Epub 2023 Sep 14. J Eur Acad Dermatol Venereol. 2024. PMID: 37643921
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study.
Kirby JS, Okun MM, Alavi A, Bechara FG, Zouboulis CC, Brown K, Santos LL, Wang A, Bibeau KB, Kimball AB, Porter ML. Kirby JS, et al. Among authors: zouboulis cc. J Am Acad Dermatol. 2024 Mar;90(3):521-529. doi: 10.1016/j.jaad.2023.10.034. Epub 2023 Oct 21. J Am Acad Dermatol. 2024. PMID: 37871805 Free article. Clinical Trial.
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC, Passeron T, Pariser D, Wozniak MB, Li X, Uhlmann L, Lobach I, Martinez AL, Ravichandran S, Alarcon I, Offidani A, Alam MS, Mendes-Bastos P. Zouboulis CC, et al. Br J Dermatol. 2024 May 17;190(6):836-845. doi: 10.1093/bjd/ljae098. Br J Dermatol. 2024. PMID: 38470171 Clinical Trial.
Adamantiades-Behçet disease: Between dermatology and ophthalmology.
Grzybowski A, Pawlikowska-Łagód K, Altenburg A, Zouboulis CC. Grzybowski A, et al. Among authors: zouboulis cc. Clin Dermatol. 2023 Jul-Aug;41(4):469-475. doi: 10.1016/j.clindermatol.2023.08.001. Epub 2023 Aug 11. Clin Dermatol. 2023. PMID: 37572969 Free article.
725 results